Alnylam Pharmaceuticals Inc Revenue Growth Rates (ALNY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Alnylam Pharmaceuticals Inc   (NASDAQ: ALNY)
 

ALNY's Revenue Growth by Quarter and Year

Alnylam Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ALNY/growth
https://api.csimarket.com/api/v1/companies/ALNY/fundamentals
https://api.csimarket.com/api/v1/companies/ALNY/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ALNY Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1,458.09
2nd Quarter June 1,290.95
1st Quarter March 1,167.18
FY 3,916.22

ALNYs Annual Revenue
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 3,713.94 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 2,248.24 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 1,828.29 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 1,037.42 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 844.29 millions




ALNY Revenue third quarter 2026 Y/Y Growth Comment
Alnylam Pharmaceuticals Inc reported Revenue increase of 16.74% year on year in the third quarter 2026, to $ 1,458.09 millions, this is lower than Alnylam Pharmaceuticals Inc 's recent average Revenue rise of 92.03%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue growth. While Alnylam Pharmaceuticals Inc ' s Revenue growth of 16.74% ranks overall at the positon no. 368 in the third quarter 2026.


ALNY Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 16.74 %
2nd Quarter June 66.86 %
1st Quarter March 96.43 %
FY   -

Financial Statements
Alnylam Pharmaceuticals Inc 's third quarter 2026 Revenue $ 1,458.09 millions ALNY's Income Statement
Alnylam Pharmaceuticals Inc 's third quarter 2025 Revenue $ 1,249.03 millions Quarterly ALNY's Income Statement


ALNY Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.95 %
2nd Quarter June 10.6 %
1st Quarter March 6.39 %
FY (Year on Year)   -


Back to ALNY Growth rate Comparisons >> Back to ALNY Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #96
Overall #368

Revenue Y/Y Growth Statistics
High Average Low
3286.23 % 92.03 % -87.9 %
(Jun 30 2020)   (Jun 30 2016)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #96
Overall #368
Revenue Y/Y Growth Statistics
High Average Low
3286.23 % 92.03 % -87.9 %
(Jun 30 2020)   (Jun 30 2016)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Alnylam Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
916.58 % 25.07 % -93.08 %
(Dec 31 2018)  


ALNY's III. Quarter Q/Q Revenue Comment
Alnylam Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue rise of 12.95% quarter on quarter, to $ 1,458.09 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Alnylam Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 719.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #120
Overall #719
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #120
Overall #719
Revenue Q/Q Growth Statistics
High Average Low
916.58 % 25.07 % -93.08 %
(Dec 31 2018)  


ALNY's III. Quarter Q/Q Revenue Comment
Alnylam Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue rise of 12.95% quarter on quarter, to $ 1,458.09 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Alnylam Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 719.


Alnylam Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 5,013.24
Y / Y Revenue Growth (TTM) 56.17 %
Year on Year Revenue Growth Overall Ranking # 2073
Seqeuential Revenue Change (TTM) 4.35 %
Seq. Revenue Growth (TTM) Overall Ranking # 2090


Cumulative Revenue growth Comment
Assuming the Alnylam Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2026, Alnylam Pharmaceuticals Inc would have reprted above average annual Revenue growth of 56.17% year on year, of $ 5,013 millions.
This marks a slow-down of the companys growth trends and from the 95.14% increase in Jun 30 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 827 to 2073.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 312
Overall # 2073

Revenue TTM Y/Y Growth Statistics
High Average Low
241.39 %
 41 %
-51.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 312
S&P 500 # 2090
Cumulative Revenue growth Comment
Assuming the Alnylam Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2026, Alnylam Pharmaceuticals Inc would have reprted above average annual Revenue growth of 56.17% year on year, of $ 5,013 millions.
This marks a slow-down of the companys growth trends and from the 95.14% increase in Jun 30 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 827 to 2073.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 312
Overall # 2073

Revenue TTM Y/Y Growth Statistics
High Average Low
241.39 %
41 %
-51.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 312
S&P 500 # 2090




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALNY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions


About Alnylam Pharmaceuticals Inc Revenue Growth Rates (ALNY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Alnylam Pharmaceuticals Inc (CIK 1178670).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001178670-26-000076
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Alnylam Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.